Pembrolizumab + Entinostat
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Trial Timeline
Feb 21, 2018 → Jan 31, 2023
NCT ID
NCT02697630About Pembrolizumab + Entinostat
Pembrolizumab + Entinostat is a phase 2 stage product being developed by Merck for Metastatic Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02697630. Target conditions include Metastatic Uveal Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Uveal Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03978624 | Phase 2 | Active |
| NCT02697630 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Uveal Melanoma